ENTX
Entera Bio Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.94
+9.70%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- -$0.07
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 7, 2026
- EPS actual
- -$0.14
- EPS estimate
- -$0.08
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -4.5%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $10
- PT range
- $9.00 – $11
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 7, 2026 | -$0.08 | -$0.14 | Miss -75.00% | — |
| May 8, 2026 | -$0.08 | -$0.07 | Beat 12.50% | — |
| Mar 27, 2026 | -$0.09 | -$0.07 | Beat 22.22% | — |
| Nov 14, 2025 | -$0.09 | -$0.07 | Beat 22.22% | — |
| Aug 8, 2025 | -$0.11 | -$0.06 | Beat 45.45% | — |
| May 9, 2025 | -$0.07 | -$0.06 | Beat 14.29% | $42.0K |
| Mar 28, 2025 | -$0.08 | -$0.06 | Beat 25.00% | $82.0K |
| Nov 8, 2024 | -$0.05 | -$0.08 | Miss -60.00% | $42.0K |
| Aug 9, 2024 | -$0.06 | -$0.06 | In line | $57.0K |
| May 10, 2024 | -$0.06 | -$0.05 | Beat 16.67% | — |
| Mar 8, 2024 | -$0.08 | -$0.07 | Beat 12.50% | $4.5M |
| Nov 14, 2023 | -$0.09 | -$0.08 | Beat 11.11% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 13, 2026